US Mail-Order Pharmacy In 1995

30 June 1996

US mail-order pharmacy sales rose 14.4% in 1995, from $5.29 billion in 1994 to $6.05 billion, says IMS America's Class of Trade Analysis.

Mail order was the fastest-growing retail sector by value, accounting for 7.8% of the total drug market. It had the largest value growth per outlet, up $370,000 against a rise of $117,00 per outlet for chain pharmacies and a rise of $89,000 for independent pharmacies. Chain pharmacies continued to hold the largest market share, and their numbers grew from 17,270 to 17,329. The number of independents fell from 24,862 to 23,067.

IMS also reports that third-parties paid for 52.8% of all US prescriptions in first-quarter 1996, with cash accounting for 34.9% and Medicaid for 12.2%. By value, third party payers accounted for 56.4% of total prescriptions, with cash at 31% and Medicaid representing 12.6%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight